Cancer-Associated Fibroblasts in Solid Tumors and Sarcomas: Heterogeneity, Function, and Therapeutic Implications

Area of Science:

• Oncology
• Cancer Biology
• Tumor Microenvironment Research

Background:

• Cancer-associated fibroblasts (CAFs) significantly influence tumor progression, immune evasion, and treatment resistance within the tumor microenvironment (TME).
• Single-cell transcriptomics reveals at least five distinct CAF subtypes (myCAFs, iCAFs, apCAFs, meCAFs, vCAFs/dCAFs) with unique characteristics.
• CAF roles are well-established in epithelial cancers, but their function in sarcomas, derived from mesenchymal cells, remains less understood, posing challenges in distinguishing malignant and stromal cells.

Purpose of the Study:

• To review the heterogeneity and plasticity of CAFs across various solid tumors.
• To focus on the specific roles of CAFs and CAF-like cells in sarcomas, including immune evasion, epithelial-to-mesenchymal transition (EMT), and therapeutic resistance.
• To explore novel strategies for targeting or reprogramming CAFs and their potential as biomarkers.

Main Methods:

• This is a narrative review synthesizing existing research on CAFs.
• Analysis of single-cell transcriptomics data to identify CAF subtypes and their functions.
• Examination of emerging evidence regarding CAF-like cells in sarcomas and their impact on tumor behavior.

Main Results:

• CAFs exhibit significant heterogeneity and plasticity, contributing to immune suppression, EMT, and resistance to various cancer therapies.
• CAF-like cells in sarcomas are implicated in tumor invasion, immune exclusion, and the formation of metastatic niches.
• CAF profiling shows promise as a biomarker for patient stratification and personalized treatment approaches.

Conclusions:

• Understanding the diverse biology of CAFs, particularly in challenging tumor types like sarcomas, is critical for advancing cancer treatment.
• Targeting or reprogramming CAFs presents a promising avenue for overcoming therapeutic resistance and improving patient outcomes.
• Further research into CAF heterogeneity and function across different cancers will facilitate the development of more effective, personalized cancer therapies.